Ticker >

Guj. Themis Biosyn share price

Gujarat Themis Biosyn Ltd.

NSE: GUJTHEMIS BSE: 506879 SECTOR: Pharmaceuticals & Drugs  57k   704   75

384.00
-0.95 (-0.25%)
BSE: 12 Apr 04:01 PM

Price Summary

Today's High

₹ 410

Today's Low

₹ 381.2

52 Week High

₹ 410

52 Week Low

₹ 141.8

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

2789.51 Cr.

Enterprise Value

2780.18 Cr.

No. of Shares

7.26 Cr.

P/E

50.75

P/B

14.6

Face Value

₹ 1

Div. Yield

0.28 %

Book Value (TTM)

₹  26.29

CASH

9.33 Cr.

DEBT

0 Cr.

Promoter Holding

70.86 %

EPS (TTM)

₹  7.57

Sales Growth

29.71%

ROE

45.92 %

ROCE

61.53%

Profit Growth

32.88 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Gujarat Themis Biosyn Ltd.

Rifamycin-S Lovastatin

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year29.71%
3 Year20.51%
5 Year30.87%

Profit Growth

1 Year32.88%
3 Year34.78%
5 Year71.85%

ROE%

1 Year45.92%
3 Year50.03%
5 Year53.99%

ROCE %

1 Year61.53%
3 Year65.78%
5 Year65.63%

Debt/Equity

0

Price to Cash Flow

70.62

Interest Cover Ratio

386.973094170404

CFO/PAT (5 Yr. Avg.)

0.566314687781693

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2023 70.86 3.3
Sep 2023 74.99 0
Jun 2023 74.99 0
Mar 2023 74.99 0
Dec 2022 74.99 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 34.7836521703425% for the Past 3 years.
  • The company has shown a good revenue growth of 20.5082905601617% for the Past 3 years.
  • Company has been maintaining healthy ROE of 50.0333672275336% over the past 3 years.
  • Company has been maintaining healthy ROCE of 65.7765022118185% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 386.973094170404.
  • The Company has been maintaining an effective average operating margins of 40.0447480456929% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of -29.5835830432625 days.
  • Company has a healthy liquidity position with current ratio of 2.2763836408402.
  • The company has a high promoter holding of 70.86%.

 Limitations

  • Promoter pledging has increased from 0% to 3.3% in 1 quarter.
  • The company is trading at a high EV/EBITDA of 36.034.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 28.17 28.17 49.59 39.65 38.86
Total Expenditure 16.05 13.25 26.08 22.83 21.11
Operating Profit 12.11 14.93 23.51 16.82 17.75
Other Income 1.81 1.4 1.08 1 1
Interest 0.07 0.03 0.03 0.05 0.08
Depreciation 0.66 0.77 0.75 0.88 0.98
Exceptional Items 0 0 0 0 0
Profit Before Tax 13.19 15.53 23.81 16.89 17.69
Tax 3.38 3.84 6.09 4.34 4.68
Profit After Tax 9.81 11.69 17.72 12.54 13.01
Adjusted EPS (Rs) 1.35 1.61 2.44 1.73 1.79

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 41.05 85.12 90.56 114.85 148.97
Total Expenditure 33.69 53.29 50.23 56.81 74.76
Operating Profit 7.36 31.84 40.33 58.05 74.22
Other Income 2.21 1.7 3.27 4.05 6.02
Interest 0.16 0.92 0.98 0.83 0.2
Depreciation 1.22 1.36 1.73 2.23 2.58
Exceptional Items 0 0 0 0 0
Profit Before Tax 8.2 31.26 40.88 59.03 77.46
Tax 1.79 7.58 10.7 15.41 19.5
Net Profit 6.41 23.67 30.18 43.62 57.97
Adjusted EPS (Rs.) 0.88 3.26 4.15 6.01 7.98

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 7.26 7.26 7.26 7.26 7.26
Total Reserves 11.26 34.93 62.68 96.06 141.88
Borrowings 0 3.18 0 0 0
Other N/C liabilities 1.43 1.36 2.49 2.02 1.9
Current liabilities 12.81 24.29 25.87 31.67 35.7
Total Liabilities 32.76 71.03 98.31 137.02 186.75
Assets
Net Block 14.61 17.08 18.95 19.43 32.66
Capital WIP 0.95 0.36 2.07 12.7 20.59
Intangible WIP 0 0 0 0 0
Investments 0 0 0 0 0
Loans & Advances 2.45 2.38 2.61 2.77 10.69
Other N/C Assets 6.71 15.12 1.31 9.21 41.53
Current Assets 8.04 36.08 73.37 92.9 81.27
Total Assets 32.76 71.03 98.31 137.02 186.75
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 8.2 31.26 40.88 59.03 77.46
Adjustment -3.92 0.65 -0.24 0.15 -2.43
Changes in Assets & Liabilities -2.45 -24.3 -19.98 -4.36 -15.11
Tax Paid -1.14 -6.97 -10.13 -14.52 -20.42
Operating Cash Flow 0.69 0.63 10.53 40.31 39.5
Investing Cash Flow -5.75 -2.98 -2.25 -29.83 -20.41
Financing Cash Flow 5.29 2.1 -5.16 -14 -13.3
Net Cash Flow 0.23 -0.26 3.12 -3.51 5.79

Corporate Actions

Investors Details

PARTICULARS Dec 2022% Mar 2023% Jun 2023% Sep 2023% Dec 2023%
promoters 74.99 74.99 74.99 74.99 70.86
anay rupen choksi 0.02 0.02 0.02 0.02 0.02
dinesh shantilal patel 0.03 0.03 0.03 0.03 0.03
jayshree d patel 0.49 0.49 0.49 0.49 0.49
nysha rupen choksi 0.02 0.02 0.02 0.02 0.02
pharmaceutical business g... 51.15 51.15 51.15 51.15 47.02
reena s patel 0.04 0.04 0.04 0.04 0.04
sachin dinesh patel 0.05 0.05 0.05 0.05 0.05
themis medicare limited 23.19 23.19 23.19 23.19 23.19
PARTICULARS Dec 2022% Mar 2023% Jun 2023% Sep 2023% Dec 2023%
investors 25.01 25.01 25.01 25.01 29.14
dipak kanayalal shah 1.04 1.05 1.05 1.05 1.05
llp - 0.13 0.15 0.02 0.15
jitendra baldwa - 1.27 1.28 1.32 -

Annual Reports

Ratings & Research Reports

Company Presentations

  • ConcallQ2FY22 23 Nov 2021
  • PresentationQ4FY22 21 Jun 2022
  • PresentationQ3FY24 12 Feb 2024
  • PresentationQ3FY22 21 Mar 2022
  • PresentationQ2FY22 22 Nov 2021
  • PresentationQ1FY21 14 Sep 2021
  • PresentationH1FY24 9 Nov 2023

Company News

Gujarat Themis Biosyn informs about loss of share certificates8 Mar 2024, 11:16AM Guj. Themis Biosyn - Quaterly Results10 Feb 2024, 11:09AM Guj. Themis Biosyn - Quaterly Results10 Feb 2024, 11:09AM Guj. Themis Biosyn - Quaterly Results10 Feb 2024, 11:09AM Gujarat Themis Biosyn informs about trading window closure27 Dec 2023, 1:09PM Gujarat Themis Biosyn informs about disclosures22 Dec 2023, 4:29PM Gujarat Themis Biosyn informs about transcript of conference call10 Nov 2023, 11:03AM Gujarat Themis Biosyn informs about newspaper publication 6 Nov 2023, 11:43AM Gujarat Themis Biosyn informs about outcome of board meeting 4 Nov 2023, 2:13PM Gujarat Themis Biosyn informs about outcome of board meeting 4 Nov 2023, 1:09PM Guj. Themis Biosyn - Quaterly Results4 Nov 2023, 11:23AM Guj. Themis Biosyn - Quaterly Results4 Nov 2023, 11:23AM Guj. Themis Biosyn - Quaterly Results4 Nov 2023, 11:23AM Gujarat Themis Biosyn informs about loss of share certificate(s)9 Oct 2023, 11:23AM Gujarat Themis Biosyn informs about loss of share certificate22 Sep 2023, 10:17AM Gujarat Themis Biosyn informs about loss of share certificate25 Aug 2023, 10:26AM Gujarat Themis Biosyn informs about newspaper advertisement17 Aug 2023, 12:10PM Guj. Themis Biosyn - Quaterly Results10 Aug 2023, 10:58AM Guj. Themis Biosyn - Quaterly Results10 Aug 2023, 10:58AM Guj. Themis Biosyn - Quaterly Results10 Aug 2023, 10:58AM Gujarat Themis Biosyn informs about loss of share certificate9 Aug 2023, 12:17PM Gujarat Themis Biosyn informs about loss of share certificate10 Jul 2023, 12:23PM Gujarat Themis Biosyn informs about loss of share certificate3 Jul 2023, 10:38AM Gujarat Themis Biosyn informs about closure of trading window 28 Jun 2023, 9:51AM Gujarat Themis Biosyn informs about loss of share certificate15 Jun 2023, 10:37AM Gujarat Themis Biosyn informs about loss of share certificate12 Jun 2023, 9:42AM Gujarat Themis Biosyn informs about loss of share certificate30 May 2023, 12:26PM Gujarat Themis Biosyn informs about investors presentation15 May 2023, 10:28AM Gujarat Themis Biosyn informs about financial highlights 15 May 2023, 10:25AM Guj. Themis Biosyn - Quaterly Results13 May 2023, 1:42PM Guj. Themis Biosyn - Quaterly Results13 May 2023, 1:42PM Guj. Themis Biosyn - Quaterly Results13 May 2023, 1:42PM Gujarat Themis Biosyn informs about loss of share certificate8 May 2023, 5:01PM Gujarat Themis Biosyn informs about conference call8 May 2023, 4:59PM Gujarat Themis Biosyn informs about details of loss of certificate27 Apr 2023, 12:28PM Gujarat Themis Biosyn informs about loss of share certificate26 Apr 2023, 2:17PM Gujarat Themis Biosyn informs about compliance certificate25 Apr 2023, 12:02PM Gujarat Themis Biosyn informs about certificate12 Apr 2023, 11:26AM Gujarat Themis Biosyn submits analyst meet intimation14 Feb 2023, 5:01PM Gujarat Themis Biosyn informs about outcome of board meeting 3 Feb 2023, 5:32PM Guj. Themis Biosyn - Quaterly Results3 Feb 2023, 11:11AM Guj. Themis Biosyn - Quaterly Results3 Feb 2023, 11:11AM Guj. Themis Biosyn - Quaterly Results3 Feb 2023, 11:11AM Gujarat Themis Biosyn informs about analyst meet31 Jan 2023, 3:29PM Gujarat Themis Biosyn informs about appointment of CFO 5 Jan 2023, 12:05PM Gujarat Themis Biosyn informs about closure of trading window26 Dec 2022, 12:51PM Gujarat Themis Biosyn informs about loss if share certificate 12 Dec 2022, 11:41AM Gujarat Themis Biosyn informs about loss of share certificate5 Dec 2022, 3:24PM Gujarat Themis Biosyn informs about loss of share certificate30 Nov 2022, 10:50AM Gujarat Themis Biosyn informs about analyst meet 29 Nov 2022, 3:47PM

Guj. Themis Biosyn Stock Price Analysis and Quick Research Report. Is Guj. Themis Biosyn an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Guj. Themis Biosyn and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Guj. Themis Biosyn cash from the operating activity was Rs 39.5009 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Guj. Themis Biosyn has a Debt to Equity ratio of 0 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Guj. Themis Biosyn , the EPS growth was 32.8821687870512 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Guj. Themis Biosyn has OPM of 49.8192624296097 % which is a good sign for profitability.
     
  • ROE: Guj. Themis Biosyn have a healthy ROE of 45.9217737246284 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Guj. Themis Biosyn is Rs 384. One can use valuation calculators of ticker to know if Guj. Themis Biosyn share price is undervalued or overvalued.
Last Updated on:
Brief about Guj. Themis Biosyn
X